A5002128895- Histiocytic Disorders and Treatments
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Eosinophilic Disorders and Syndromes
- Magnesium in Health and Disease
- Chronic Myeloid Leukemia Treatments
- Acute Myeloid Leukemia Research
- Extracellular vesicles in disease
- Tumors and Oncological Cases
- Mast cells and histamine
- COVID-19 Clinical Research Studies
- Sarcoidosis and Beryllium Toxicity Research
- SARS-CoV-2 and COVID-19 Research
- Viral-associated cancers and disorders
- Parvovirus B19 Infection Studies
- Chronic Lymphocytic Leukemia Research
- Cancer Immunotherapy and Biomarkers
- Lymphoma Diagnosis and Treatment
- Parathyroid Disorders and Treatments
- Pneumocystis jirovecii pneumonia detection and treatment
- Hemophilia Treatment and Research
- Diabetes and associated disorders
- Lung Cancer Treatments and Mutations
- Inflammasome and immune disorders
- Radiomics and Machine Learning in Medical Imaging
- Neutropenia and Cancer Infections
Mayo Clinic in Arizona
2018-2025
Mayo Clinic
2018-2024
WinnMed
2020-2024
Mayo Clinic in Florida
2024
Sorbonne Université
2020
Pitié-Salpêtrière Hospital
2020
Assistance Publique – Hôpitaux de Paris
2020
Cliniques Universitaires Saint-Luc
2020
Walker (United States)
2020
University of Alabama at Birmingham
2020
Abstract Erdheim-Chester disease (ECD) and Rosai-Dorfman (RDD) are rare non-Langerhans cell histiocytoses (non-LCHs), for which therapeutic options limited. MAPK pathway activation through BRAFV600E mutation or other genomic alterations is a histiocytosis hallmark correlates with favorable response to BRAF inhibitors the MEK inhibitor cobimetinib. However, there has been no systematic evaluation of alternative inhibitors. To assess efficacy safety trametinib, we retrospectively analyzed...
Rosai-Dorfman disease (RDD) is a rare histiocytic neoplasm with recent studies showing alterations in the MAPK pathway, most commonly KRAS and MEK genes about 40% of patients. Reports on use MEK-inhibitor therapy RDD have been limited to small case studies. There are no approved treatments for this neoplasm, therefore patients need efficacious treatments.To study outcomes after treatment cobimetinib based pathway RDD.This retrospective cohort conducted at 2 tertiary care centers included who...
Malignant histiocytosis (MH) is an extremely rare neoplasm of the macrophage-dendritic cell lineage. We report clinical characteristics, molecular aberrations, treatments, and outcomes patients with MH seen at two referral centers from January 2000 to May 2023. identified 43 MH, which 26 had histiocytic sarcoma (MH-H), 9 interdigitating dendritic (MH-IDC), 8 Langerhans (MH-LC). The median age diagnosis was 61 years (range, 3-83). Thirty-three (77%) multifocal disease, while 10 unifocal...
Advances in the treatment of Langerhans cell histiocytosis (LCH) have resulted a growing survivor population. There is lack data on long-term outcomes among adults with LCH. We conducted retrospective record review 219 (aged ≥18 years) Most common presentation was multisystem (34.2%), followed by single-system pulmonary (32%), unifocal (28.3%), and multifocal (5.5%) Risk organ involvement (the liver, spleen, or bone marrow) seen 8.7% cases, 40 88 (45.5%) tested cases were BRAFV600E. At...
Despite extensive research, the specific factor associated with SARS-CoV-2 infection that mediates life-threatening inflammatory cytokine response in patients severe COVID-19 remains unidentified. Herein we demonstrate virus-encoded Open Reading Frame 8 (ORF8) protein is abundantly secreted as a glycoprotein vitro and symptomatic COVID-19. ORF8 specifically binds to NOD-like receptor family pyrin domain-containing 3 (NLRP3) CD14+ monocytes induce inflammasomal cytokine/chemokine responses...
Abstract Langerhans cell histiocytosis (LCH) is a rare histiocytic neoplasm. To date, there lack of U.S. Food and Drug Administration–approved treatments in adult LCH to establish optimal first-line therapy. We conducted retrospective, single-center case series evaluating the use BRAF inhibitors patients with BRAFV600E- proven by biopsy. Our first report as therapy adults LCH. also efficacy single-agent dabrafenib All but one our had favorable response targeted
Abstract Erdheim–Chester disease (ECD) is a histiocytic neoplasm that predominantly harbors mitogen‐activated protein kinase (MAPK) pathway variants. MAPK inhibitors typically are effective treatments, but mutations outside the pathway, such as CSF1R variants, may cause refractory ECD. We describe patient with novel somatic mutation in ( R549_E554delinsQ ) resulted ECD affecting central nervous system. Cell model studies, RNA sequencing analysis, and silico modeling suggested she had...
Langerhans cell histiocytosis (LCH) is a histiocytic neoplasm that can involve the lungs as single system (LCH-SSL) or multisystem disease (LCH-MSL). The role of full-body radiographic staging to determine whether patients have LCH-SSL LCH-MSL unclear. Long-term outcomes versus and without lung involvement (LCH-MSNL) are unknown. A retrospective study adult LCH seen at our center from January 2000 2020 was performed. In Part 1, we addressed utility whole-body imaging among those presenting...
Chronic neutrophilic leukemia (CNL) is a rare and aggressive BCR-ABL1 (Philadelphia chromosome) negative myeloproliferative neoplasm that carries poor prognosis.It defined by persistent mature leukocytosis, bone marrow granulocytic hyperplasia, hepatosplenomegaly 1 .Despite the 2013 seminal discovery of oncogenic driver mutations in colony-stimulating factor 3 receptor (CSF3R) CNL 2 , no standard care exists.Chemotherapy not able to provide durable responses, literature on allogeneic stem...
ABSTRACT COVID-19 is a significant cause of morbidity and mortality in blood cancer patients, especially those on immunosuppressive therapy. Despite extensive research, the specific factor associated with SARS-CoV-2 infection that mediates life-threatening inflammatory cytokine response patients severe remains unidentified. Herein we demonstrate virus-encoded Open Reading Frame 8 (ORF8) protein abundantly secreted as glycoprotein vitro symptomatic COVID-19. ORF8 specifically binds to...
ObjectiveTo distinguish between sepsis only vs progressive lymphoma in patients with a history of who present to the hospital lactic acidosis.Patients and MethodsWe identified non-Hodgkin (NHL) or Hodgkin from January 2014 December 2015. Patients were categorized into 2 groups: lymphoma. Two-sided Wilcoxon rank sum test χ2Kraut J.A. Madias N.E. Lactic acidosis.N Engl J Med. 2014; 371: 2309-2319Crossref PubMed Scopus (376) Google Scholar/Fisher exact used compare continuous categorical...
PURPOSE BRAF and MEK inhibitors are standard treatments in histiocytic disorders, such as Erdheim-Chester disease (ECD). Some patients lack MAPK-pathway alterations, making these less effective. METHODS We describe three with disorders who have novel non-MAPK pathway alterations. These alterations were studied through genomic silico analyses when applicable, then treated off-label medications rationally selected on the basis of RESULTS Patient 1 had rapidly progressive ECD involving CNS. A...
Abstract Magnesium is an essential element that involved in critical metabolic pathways. A diet deficient magnesium associated with increased risk of developing cancer. Few studies have reported whether a serum level below the reference range (RR) prognosis patients diffuse large B cell lymphoma (DLBCL). Using retrospective approach DLBCL undergoing autologous stem transplant (AHSCT), we evaluated association hypomagnesemia survival. Totally, 581 eligible for AHSCT during immediate...
An algorithmic approach, termed the prolonged clot time profile (PROCT), consisting of initial screening with prothrombin (PT) and activated partial thromboplastin (aPTT), reflexive mixing studies if indicated, follow-up assays depending on testing results, offers an efficient approach to delineate etiology a PT/aPTT. Herein, we present outcomes PROCT in outpatient setting.In this retrospective study, reviewed medical records consecutive outpatients who had PT and/or aPTT noted routine...